Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Eli Lilly (LLY) closed at $786.92 in the latest trading session, marking a +1.19% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.61% for the day. On the other ...

Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

AI is reshaping life sciences. Learn how compliant, explainable, and genuinely useful systems move from pilot to scale and ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

Irish-made medicines heading to the US face steep new duties, raising alarm among patients, producers and investors on both ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...